Log In
BCIQ
Print this Print this
 

Extina, ketoconazole

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionFoam formulation of 2% ketoconazole
Molecular Target Cytochrome P450 C-14 alpha demethylase (CYP51)
Mechanism of ActionCytochrome P450 C-14 alpha demethylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsTreat seborrheic dermatitis; Treat seborrheic dermatitis fungal infections
Regulatory Designation
PartnerMylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/17/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today